Selvaraj Ramesh K, Geiger Terrence L
Department of Pathology, St. Jude Children's Research Hospital, 332 North Lauderdale Street, Memphis, TN 38105, USA.
J Immunol. 2007 Jun 15;178(12):7667-77. doi: 10.4049/jimmunol.178.12.7667.
TGF-beta induces Foxp3 expression in stimulated T cells. These Foxp3 cells (induced regulatory T cells (iTreg)) share functional and therapeutic properties with thymic-derived Foxp3 regulatory T cells (natural regulatory T cells (nTreg)). We performed a single-cell analysis to better characterize the regulation of Foxp3 in iTreg in vitro and assess their dynamics after transfer in vivo. TGF-beta up-regulated Foxp3 in CD4(+)Foxp3 T cells only when added within a 2- to 3-day window of CD3/CD28 stimulation. Up to 90% conversion occurred, beginning after 1-2 days of treatment. Foxp3 expression strictly required TCR stimulation but not costimulation and was independent of cell cycling. Removal of TGF-beta led to a loss of Foxp3 expression after an approximately 4-day lag. Most iTreg transferred into wild-type mice down-regulated Foxp3 within 2 days, and these Foxp3 cells were concentrated in the blood, spleen, lung, and liver. Few of the Foxp3 cells were detected by 28 days after transfer. However, some Foxp3 cells persisted even to this late time point, and these preferentially localized to the lymph nodes and bone marrow. CXCR4 was preferentially expressed on Foxp3 iTreg within the bone marrow, and CD62L was preferentially expressed on those in the lymph nodes. Like transferred nTreg and in contrast with revertant Foxp3 cells, Foxp3 iTreg retained CD25 and glucocorticoid-induced TNFR family-related gene. Thus, Foxp3 expression in naïve-stimulated T cells is transient in vitro, dependent on TGF-beta activity within a highly restricted window after activation and continuous TGF-beta presence. In vivo, a subset of transferred iTreg persist long term, potentially providing a lasting source for regulatory activity after therapeutic administration.
转化生长因子-β(TGF-β)可诱导受刺激的T细胞表达叉头框蛋白3(Foxp3)。这些Foxp3细胞(诱导性调节性T细胞(iTreg))与胸腺来源的Foxp3调节性T细胞(天然调节性T细胞(nTreg))具有相同的功能和治疗特性。我们进行了单细胞分析,以更好地表征体外iTreg中Foxp3的调控,并评估其体内转移后的动态变化。仅在CD3/CD28刺激的2至3天窗口期内添加TGF-β时,它才会使CD4(+)Foxp3 T细胞中的Foxp3上调。治疗1至2天后开始出现高达90%的转化率。Foxp3的表达严格需要TCR刺激,但不需要共刺激,且与细胞周期无关。去除TGF-β后,大约4天的延迟后Foxp3表达丧失。大多数转移到野生型小鼠体内的iTreg在2天内下调Foxp3,这些Foxp3细胞集中在血液、脾脏、肺和肝脏中。转移后28天几乎检测不到Foxp3细胞。然而,一些Foxp3细胞甚至在这个晚期时间点仍持续存在,并且这些细胞优先定位于淋巴结和骨髓。趋化因子受体4(CXCR4)在骨髓中的Foxp3 iTreg上优先表达,而淋巴细胞功能相关抗原-1(CD62L)在淋巴结中的Foxp3 iTreg上优先表达。与转移的nTreg一样,与恢复性Foxp3细胞相反,Foxp3 iTreg保留了CD25和糖皮质激素诱导的肿瘤坏死因子受体家族相关基因。因此,幼稚刺激T细胞中Foxp3的表达在体外是短暂的,取决于激活后高度受限窗口期内的TGF-β活性以及持续的TGF-β存在。在体内,一部分转移的iTreg长期持续存在,可能为治疗给药后提供持久的调节活性来源。